null

null

null

null

null

null

null

null

null

Near-zero debt; cash-funded clinical-stage biotech with no material long-term borrowings; 20% rate rise has negligible P&L impact

Minimal; company holds cash/equivalents and has no floating-rate debt, so rising rates marginally improve interest income, not a liability risk

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API synthesis likely dependent on European/Asian CMOs; key chokepoints are Indian API manufacturing hubs and Chinese raw chemical intermediates

Pre-revenue; no international revenue markets yet; currency devaluation exposure is essentially nil at current stage

Operations primarily UK/Switzerland; no commercial revenue streams; FX exposure limited to GBP/CHF/USD operating cost translation

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or dual CMO partners for OK-101 drug substance; likely non-substitutable on short notice given regulatory filing requirements

Pre-commercial pharma R&D; no cloud-dependent revenue platform; account termination would disrupt internal ops but not a revenue-critical risk

Clinical-stage biopharma; secondary model is potential licensing/partnering of assets; cloud termination risk is operationally minor

Low API coupling risk; company uses standard scientific/clinical software; no proprietary API integrations underpinning revenue

Low Howey risk; revenue model is pharmaceutical drug licensing/sales, not an investment contract; no token or passive-return structure

Very High

Moderate; clinical trial patient data subject to GDPR (EU trials); CCPA exposure minimal given no US consumer-facing commercial product yet

Negligible; single-asset ophthalmology biotech with no market share; no horizontal or vertical antitrust concern at current scale

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue currently; 100% transactional/milestone-based future model via licensing deals or eventual drug sales

Primary monetization via licensing milestones and royalties on OK-101 (dry eye/ocular GvHD); potential pharma partnership deal fees

Drug pricing will follow specialty ophthalmology benchmarks (~$3,000–$15,000/year); pricing power contingent on Phase 3 efficacy and FDA/EMA label

Moderate-to-high if approved; orphan/specialty ophthalmic drugs carry pricing leverage, but payer pushback in dry eye is significant

Expected 70–85% gross margin post-commercialization, typical for specialty pharma with outsourced manufacturing

No free-rider problem; prescription drug with no generic equivalent during patent life; physician/patient switching costs are moderate

Growth is sublinear to headcount; clinical and regulatory milestones drive value, not staff scaling; commercialization would require a step-change sales force

Marginal cost of growth is capital-intensive pre-approval (trials), then drops sharply if partnered; self-commercialization would be headcount-linear

Not applicable; company is not a franchise model

At 10x scale (post-approval), CAC shifts to physician detailing cost; estimated $500–$2,000 per prescribing physician in specialty ophthalmic segment

No network effects; pharmaceutical products do not exhibit user-growth compounding; value is IP and clinical data, not network scale

AI displacement risk low for core asset (novel lipid peptide drug); AI may accelerate discovery but does not obsolete existing clinical-stage compound

Moderate resilience; severe dry eye and ocular GvHD are chronic conditions with medical need, but elective/mild cases may defer treatment in downturns

Ophthalmologists and corneal specialists prescribing for dry eye disease (DED) and ocular graft-versus-host disease

Hematology/oncology centers managing GvHD patients; potential institutional hospital formulary customers for ocular GvHD indication

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital fully directed to future-state (clinical trials, IP); zero legacy infrastructure; R&D spend ~95% of total opex; no reallocation tension

0001849296

OKYO